![]() Possible explanations are differences in characteristics, quality of esophageal cancer care, or differential strategies for evaluation of recurrence. After the matching procedure, the median disease-free survival was 17.2 months and median overall survival was 28.2 months.ĭisease-free survival in our population-based study was considerably longer than the placebo population of CheckMate-577 (19.7 versus 11.0 months). Median disease-free survival was 19.7 months and median overall survival was 32.2 months. Sixty percent of patients were diagnosed with recurrence or were deceased at the end of follow-up. In addition, to adjust for differences in characteristics between CheckMate 577 and our population-based cohort, a matching-adjusted indirect comparison was performed for pathological lymph node status and pathological tumor status. Disease-free and overall survival were assessed from 12 weeks after resection using Kaplan-Meier methods. Patients with cervical esophageal cancer, irradical resection, or complete pathological response were excluded. Resected patients with stage II/III esophageal or gastroesophageal junction cancer (2015-2016) treated with neoadjuvant chemoradiotherapy were selected from the Netherlands Cancer Registry. The aim of our study was to investigate disease-free and overall survival in a nationwide population aligned with the inclusion criteria of CheckMate 577. Population-based data can provide insights in outcomes from clinical practice. Results of CheckMate 577 show an improved disease-free survival for patients with resected esophageal or gastroesophageal junction cancer treated with adjuvant nivolumab compared with placebo (22.4 versus 11.0 months). 9 Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT Utrecht, The Netherlands.8 Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.7 Department of Medicine, University Hospital, Johannes Gutenberg University Mainz, Mainz, Germany. ![]() 6 Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.5 Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.4 Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.3 Department of Medical Oncology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.2 Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.1 Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), The Netherlands.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |